Clinical trial · Observational
Massive Nasal Bleeding in Patients With NPC Received Curative RT
Massive Nasal Bleeding in Patients With Nasopharyngeal Carcinoma Received Curative Radiotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the incidence, predictive markers, and survival impact of massive nasal bleeding in nasopharyngeal carcinoma (NPC) patients who received curative radiotherapy (RT) with/without chemotherapy. A total of 1327 patients with previously untreated, biopsy-proven NPC, and no distant metastasis were retrospective reviewed. Investigators analyzed the occurrence rates of massive nasal bleeding between different characteristics and tried to identify important predictive factors. Investigators compared overall survival between patients with and without massive nasal bleeding by Kaplan-Meier method.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma Patients Treated With Curative Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patients with massive nasal bleeding | Other | — | UNRESOLVED |
| Patients without massive nasal bleeding | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- NPC received Curative radiotherapy
- interventionNames
- Other: Patients without massive nasal bleeding
- Other: Patients with massive nasal bleeding
Primary outcomes (1)
- measure
- Massive Nasal Bleeding Rate
- timeFrame
- From date of radiotherapy until the date of first documented massive bleeding, assessed up to 360 months
- description
- Massive Nasal Bleeding Rate among different characteristics. Massive Nasal Bleeding was defined as unique blood loss \> 300 ml or recurrent blood losses \> 100 ml.
Secondary outcomes (1)
- measure
- Overall Survival
- timeFrame
- From date of radiotherapy until the date of last clinic visit or date of death from any cause, whichever came first, assessed up to 360 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * previously untreated, biopsy-proven NPC * no distant metastasis Exclusion Criteria: * incomplete record of history or treatment
References
Publications (4)
- BACKGROUNDHuang Y, Yan D, Wang M, Chen S, Yang F. Clinicopathological factors affecting the prognosis of massive hemorrhage after radiotherapy for patients having nasopharyngeal carcinoma. J Cancer Res Ther. 2021 Nov;17(5):1219-1224. doi: 10.4103/jcrt.jcrt_586_21. PMID 34850770
- BACKGROUNDZhan J, Zhang S, Wei X, Fu Y, Zheng J. Etiology and management of nasopharyngeal hemorrhage after radiotherapy for nasopharyngeal carcinoma. Cancer Manag Res. 2019 Mar 15;11:2171-2178. doi: 10.2147/CMAR.S183537. eCollection 2019. PMID 30936749
- BACKGROUNDLi J, Yi X, He G, Yao D, Bin X, Feng Y, Niu Z, Tan Q, Tang A. Analysis of the risk of death and clinical management for nasal or nasopharyngeal bleeding occurring after radiotherapy for nasopharyngeal carcinoma. Auris Nasus Larynx. 2022 Aug;49(4):703-708. doi: 10.1016/j.anl.2022.01.006. Epub 2022 Jan 20. PMID 35065845
- BACKGROUNDZeng L, Wan W, Luo Q, Jiang H, Ye J. Retrospective analysis of massive epistaxis and pseudoaneurysms in nasopharyngeal carcinoma after radiotherapy. Eur Arch Otorhinolaryngol. 2022 Jun;279(6):2973-2980. doi: 10.1007/s00405-021-07111-x. Epub 2021 Oct 8. PMID 34623497